Evidence map›Paper›PMID 41554333›Full record

ArticleContemporary clinical trials2026

Expanding access to cancer genetic care for cancer survivors: Rationale and design for a randomized controlled trial of a chatbot-based genetic education and testing.

Jinghua An, Maisha Huq, Erin Speiser, Sherry Grumet, Beth N Peshkin, Emily Heidt, Lucile Adams-Campbell, Christopher Grisham, Samuel Tundealao, Rose Yesha and 10 more

Registry-linked trialAbstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in Contemporary clinical trials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06073626 (Addressing Genomic Disparities in Cancer Survivors), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06073626 narecruitingnot on this map

Addressing Genomic Disparities in Cancer Survivors

TypeinterventionalSponsorRutgers, The State University of New JerseyRan2024 to 2027Enrolled428ConditionsHereditary Cancer, Genetic TestingArmsRelational agent (RA) / Chatbot, Enhanced Usual Care (EUC)
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Jinghua AnRutgers Cancer Institute, Rutgers University, 195 Little Albany St, New Brunswick, NJ 08901, USA; Indiana University School of Nursing, 600 Barnhill Dr, Indianapolis, IN 46202, USA.
Maisha HuqGeorgetown University, Lombardi Comprehensive Cancer Center, 3800 Reservoir Rd NW, Washington, DC 20007, USA; Jess and Mildred Fisher Center for Hereditary Cancer and Clinical Genomics Research, 2115 Wisconsin Ave NW, Washington, DC 20007, USA.
Erin SpeiserRutgers Cancer Institute, Rutgers University, 195 Little Albany St, New Brunswick, NJ 08901, USA.
Sherry GrumetRutgers Cancer Institute, Rutgers University, 195 Little Albany St, New Brunswick, NJ 08901, USA.
Beth N PeshkinGeorgetown University, Lombardi Comprehensive Cancer Center, 3800 Reservoir Rd NW, Washington, DC 20007, USA; Jess and Mildred Fisher Center for Hereditary Cancer and Clinical Genomics Research, 2115 Wisconsin Ave NW, Washington, DC 20007, USA.
Emily HeidtRutgers Cancer Institute, Rutgers University, 195 Little Albany St, New Brunswick, NJ 08901, USA.
Lucile Adams-CampbellGeorgetown University, Lombardi Comprehensive Cancer Center, 3800 Reservoir Rd NW, Washington, DC 20007, USA.
Christopher GrishamGeorgetown University, Lombardi Comprehensive Cancer Center, 3800 Reservoir Rd NW, Washington, DC 20007, USA.
Samuel TundealaoRutgers Cancer Institute, Rutgers University, 195 Little Albany St, New Brunswick, NJ 08901, USA; School of Public Health, Rutgers University, 683 Hoes Ln W, Piscataway, NJ 08854, USA.
Rose YeshaMedStar Health Research Institute, 10980 Grantchester Way 7th Floor, Columbia, MD 21044, USA.
Deborah ToppmeyerRutgers Cancer Institute, Rutgers University, 195 Little Albany St, New Brunswick, NJ 08901, USA.
Claudine IsaacsGeorgetown University, Lombardi Comprehensive Cancer Center, 3800 Reservoir Rd NW, Washington, DC 20007, USA; Jess and Mildred Fisher Center for Hereditary Cancer and Clinical Genomics Research, 2115 Wisconsin Ave NW, Washington, DC 20007, USA.
Lia SorgenGeorgetown University, Lombardi Comprehensive Cancer Center, 3800 Reservoir Rd NW, Washington, DC 20007, USA.
Naomi TanRutgers Cancer Institute, Rutgers University, 195 Little Albany St, New Brunswick, NJ 08901, USA; Robert Wood Johnson Medical School, Rutgers University, 125 Paterson St, New Brunswick, NJ 08901, USA.
Anupama Hooda-NehraRutgers Cancer Institute, New Jersey Medical School, Rutgers University, 185 S Orange Ave, Newark, NJ 07103, USA.
Melanie A NixRutgers Cancer Institute, Rutgers University, 195 Little Albany St, New Brunswick, NJ 08901, USA.
Dorothy J ReedRutgers Cancer Institute, Rutgers University, 195 Little Albany St, New Brunswick, NJ 08901, USA.
Jimmie StatonRutgers Cancer Institute, Rutgers University, 195 Little Albany St, New Brunswick, NJ 08901, USA.
Marc D SchwartzGeorgetown University, Lombardi Comprehensive Cancer Center, 3800 Reservoir Rd NW, Washington, DC 20007, USA; Jess and Mildred Fisher Center for Hereditary Cancer and Clinical Genomics Research, 2115 Wisconsin Ave NW, Washington, DC 20007, USA.
Anita Y KinneyRutgers Cancer Institute, Rutgers University, 195 Little Albany St, New Brunswick, NJ 08901, USA; School of Public Health, Rutgers University, 683 Hoes Ln W, Piscataway, NJ 08854, USA. Electronic address: anita.kinney@rutgers.edu.

Funding

Multilevel factors associated with disparities in the use of targeted cancer therapies in MedicareR01CA277599 · NCI · RUTGERS BIOMEDICAL AND HEALTH SCIENCES · PI Anita Y. Kinney, Marc D Schwartz · 2023 to 2026
$2.7M
Training Program in Cancer Population Science (CaPS)T32CA261787 · NCI · GEORGETOWN UNIVERSITY · PI Lucile L. Adams-Campbell, Suzanne C. O'Neill · 2021 to 2026
$1.1M
NCI NIH HHS R01 CA277599NCI NIH HHS T32 CA261787
6 · The paper itself

Abstract

backgroundDespite national guidelines recommending germline genetic testing (GT) for cancer survivors at high risk for hereditary cancers, GT remains underutilized, particularly among underserved populations who experience significant population health differences and higher cancer mortality. Barriers at the individual, interpersonal, and system levels contribute to this underutilization. Proactive clinical outreach and technology-based tools such as chatbots may help address these barriers and streamline cancer genetic service delivery, but culturally tailored chatbot interventions have rarely been tested for efficacy in Black cancer survivors. This paper describes the formative research and protocol for a multisite, randomized controlled trial testing a streamlined care delivery model addressing multilevel barriers to GT uptake.

methodsUsing electronic health records from two health systems, we will proactively identify and enroll 428 Black patients who have a prior diagnosis of breast, ovarian, uterine, colorectal, prostate, or pancreatic cancer and meet national guideline criteria for genetic testing. Participants are randomized to either the Genetic Education Decision Assistant (GEDA), a chatbot-based intervention, or Enhanced Usual Care (EUC, a clinical letter recommending genetic counseling and testing). The primary outcome is genetic testing completion. Secondary outcomes include genetic counseling uptake, knowledge, psychological distress, and decision regret, satisfaction, and conflict. DISCUSSION: This ongoing trial addresses an important translational gap by developing and implementing an alternative care delivery model that includes a chatbot to provide streamlined cancer genetic services. If effective, this intervention has the potential to reduce population differences in cancer genetics care and guide cancer risk reduction, surveillance, and cascade testing. TRIAL REGISTRATION NUMBER: The trial is registered on clinicaltrials.gov (NCT06073626).

Indexed as

Black or African AmericanCancer SurvivorsGenetic CounselingGenetic TestingHealth Services AccessibilityNeoplasmsPatient Education as TopicFemaleHumansMaleMulticenter Studies as TopicRandomized Controlled Trials as Topiccancer genetic risk assessmentChatbotGenetic counselingGenetic educationGenetic testingHealth disparityHereditary cancer

Identifiers

PMID41554333
PMCPMC13113580

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.